UK markets close in 4 hours 58 minutes
  • FTSE 100

    7,492.19
    +4.04 (+0.05%)
     
  • FTSE 250

    19,962.81
    +50.41 (+0.25%)
     
  • AIM

    913.21
    -1.54 (-0.17%)
     
  • GBP/EUR

    1.1822
    +0.0003 (+0.02%)
     
  • GBP/USD

    1.2091
    +0.0015 (+0.12%)
     
  • BTC-GBP

    19,079.88
    -392.63 (-2.02%)
     
  • CMC Crypto 200

    536.37
    -20.98 (-3.76%)
     
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • DOW

    32,774.41
    -58.13 (-0.18%)
     
  • CRUDE OIL

    89.56
    -0.94 (-1.04%)
     
  • GOLD FUTURES

    1,809.80
    -2.50 (-0.14%)
     
  • NIKKEI 225

    27,819.33
    -180.63 (-0.65%)
     
  • HANG SENG

    19,610.84
    -392.60 (-1.96%)
     
  • DAX

    13,560.73
    +25.76 (+0.19%)
     
  • CAC 40

    6,488.57
    -1.43 (-0.02%)
     

QIAGEN N.V.: QIAGEN increases full-year 2022 outlook

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

QIAGEN N.V. / Key word(s): Change in Forecast
QIAGEN N.V.: QIAGEN increases full-year 2022 outlook

26-Jul-2022 / 19:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN increases full-year 2022 outlook

Venlo, The Netherlands, July 26, 2022 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS).

QIAGEN increases the outlook for net sales to at least $2.2 billion CER (prior outlook for at least $2.12 billion CER), and for adjusted diluted EPS to at least $2.30 CER per share (prior outlook for at least $2.14 CER).

This update includes a reaffirmation of the goal for double-digit CER sales growth from the non-COVID product groups, which grew 12% CER in the first half of 2022, but for a decline in COVID-19 sales amid volatile pandemic trends. It also reflects an updated review of current macro-economic issues, including inflation and energy supplies. Also taken into consideration is the adverse impact on sales resulting from the war in Ukraine, and related decisions to suspend business in Russia and Belarus (which represented about 1% of total QIAGEN sales in 2021).

QIAGEN continues to make significant investments into its portfolio, in particular the Five Pillars of Growth, for new products, test menu and applications. The outlook does not take into consideration any future acquisitions.

 

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

 

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

 

Contacts QIAGEN N.V.:
John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com

26-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

Netherlands

Phone:

+31 7735566 - 00

Fax:

+31 77 35566-58

E-mail:

qiagen@qiagen.com

Internet:

www.qiagen.com

ISIN:

NL0012169213

WKN:

A2DKCH

Indices:

DAX, TecDAX

Listed:

Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX

EQS News ID:

1406431


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting